Impact of Neuropathic Post-Zosterian Pain on the Cognition

Cognition Clinical Trial

Official title:

Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00989040
• Other study ID #: CHU-0049
• Status: Completed
• Phase: Phase 1
• First received: March 13, 2009
• Last updated: January 26, 2012
• Start date: March 2009
• Est. completion date: September 2009

Study information

• Verified date: January 2012
• Source: University Hospital, Clermont-Ferrand
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. These consequences could be increased with usual treatment. So the aim of this study is to explore these cognitive consequences.

Description:

Pilot prospective study with parallel groups

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Patient suffering of NPZ pain

• Over 55 years old

• Healthy volunteers

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Cognition
• Neuropathic Post-zosterian Pain

Intervention

Drug:
• usual treatment: Versatis
To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain. To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch.

Locations

Country	Name	City	State
France	CHU Clermont-Ferrand	Clermont-Ferrand

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The principal outcome is to explore if the cognition is failed in treated patients suffering of neuropathic post-zosteria pain.		at day 1	Yes
Secondary	Study if treated patients with patch (Versatis®) have better cognition than treated patients without patch.		at day 1	Yes